{"id":10088,"date":"2026-09-17T09:37:56","date_gmt":"2026-09-17T08:37:56","guid":{"rendered":"https:\/\/www.library.sath.nhs.uk\/research\/?p=10088"},"modified":"2026-09-17T09:37:57","modified_gmt":"2026-09-17T08:37:57","slug":"carbapenem-resistant-enterobacterales-across-the-uk-a-nationwide-study-of-carbapenemase-testing-and-novel-antimicrobial-activity-2026","status":"publish","type":"post","link":"https:\/\/www.library.sath.nhs.uk\/research\/2026\/09\/17\/carbapenem-resistant-enterobacterales-across-the-uk-a-nationwide-study-of-carbapenemase-testing-and-novel-antimicrobial-activity-2026\/","title":{"rendered":"Carbapenem-resistant Enterobacterales across the UK: A nationwide study of carbapenemase testing and novel antimicrobial activity (2026)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Type of publication:<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Journal article<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Author(s):<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Baltas I.; Drury K.; Harrison T.; Moore N.; Lester R.; Chattaway M.A.; England B.; Cattrall J.W.S.; Donaldson C.J.; Jamal Khan D.P.; Carroll A.; Ball D.; Wareham D.W.; Pahalage R.; Banavathi K.; Drazho B.; Shorrocks R.E.; Hlaing W.; Adhikaree N.; Ryan F.; Thompson J.V.; Connolly G.; Shibu P.; Ale E.; Mirfenderesky M.; Jain S.; Fowler S.; Beard K.; Hughes G.; Bonnici G.; Mohammed T.; Brown K.; Drazich-Taylor S.; Martinez A.S.; Lipworth S.; Crawford-Jones D.; Elnour M.; Moore J.; Democratis J.; McCormick J.; Hussain A.; Islam J.; Jenkins D.; Stoesser N.; Hopkins K.; Demirjian A.; Hatcher J.; Soares A.L.; Kirby A.; Grandjean L.; Riley U.; Stephens J.; Joseph A.; Winzor G.; Jackson K.E.; Kandil H.; Barker B.; Planche T.; Jawad S.; Merrick B.; Snell L.B.; Subbaraj K.P.; Munthali P.G.; Clayton J.J.; Varghese R.; Jones C.R.; Hardman N.L.; Komosa M.M.; Heppell B.M.; Halstead F.D.; Qaiser S.; Mavrogiorgou E.; Nye C.; Bamber S.; Locke T.E.; Whatmore J.; Mohamed F.; Adobah E.; Knox K.; Campbell O.; Carson A.A.; North P.; Albur M.; Tickell-Painter M.; Mooney H.; Coward A.; Shah A.; Choudhury R.Y.; Sughayer H.M.; Graham C.; Mutch C.P.; Dewar S.; Hesing S.C.; Khan S.; Garcia-Mingo A.; Garcia D.M.; Penciu F.; Kosaraju K.; Davey E.; Vazquez A.M.; Qazzafi Z.; *Anand M.; Navalan H.; Roberts S.; Mermerelis D.; Read A.; Rangaiah J.; Austin-Hutchison R.; Price J.R.; Peters J.; Stevens M.; Knapper F.; Merchant N.; Davies F.; Vanstone G.L.; Allen D.; Prior-ong M.; Tuharska Z.; Soper I.; Tsui R.; Watts A.; Kakkar N.; Patel M.; Townsley H.; Saajan P.; Claxton A.P.; Burns P.J.; Jeppesen C.A.; Lee M.; Tudor A.; Macnaughton E.; McKeating C.; Dhillon R.; Okoliegbe I.; Sakka N.E.; Scott K.S.; Wang D.B.; Wilson B.; Laing-Herridge K.; Diver-Hall E.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Citation:<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">International Journal of Antimicrobial Agents. 67(10) (no pagination), 2026. Article Number: 107898. Date of Publication: 01 Oct 2026. [epub ahead of print]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Abstract:<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Background Carbapenem-resistant Enterobacterales (CRE) are increasing in the UK, but the drivers of this rise and effective treatment options remain uncertain. Methods Ninety-seven acute National Health Service Trusts, including 192 UK hospitals, submitted data on 8840 consecutive, non-duplicate CRE (October 2023 to September 2024) and local laboratory methods. Results Predominant CRE species were Klebsiella pneumoniae (30.6%, 2709\/8840), Escherichia coli (29.3%, 2592\/8840), Enterobacter cloacae complex (22.2%, 1966\/8840). Overall, 21.8% (1927\/8840) of CRE were collected in outpatient settings. Overall, 85.5% (7279\/8513) of CRE underwent carbapenemase detection testing, with significant variation depending on species, specimen type, and baseline antibiogram. Carbapenemases detected were OXA-48-like (22.3%, 1967\/8840), NDM (18.6%, 1645\/8840), KPC (9.2%, 817\/8840), IMP (2.0%, 178\/8840), VIM (0.7%, 62\/8840), multi-carbapenemase producers (4.0%, 351\/8840). Overall, 51.2% (4526\/8840) of CRE were tested against &gt;=1 novel agent. In-house antimicrobial susceptibility testing availability was common for ceftazidime-avibactam (90.7%, 88\/97) and cefiderocol (73.2%, 71\/97), while less common for meropenem-vaborbactam (41.2%, 40\/97), imipenem-relebactam (21.6%, 21\/97), aztreonam-avibactam (11.3%, 11\/97). OXA-48-like- (97.6%, 1138\/1166) and KPC producers (96.2%, 429\/446) remained susceptible to ceftazidime-avibactam; KPC producers to meropenem-vaborbactam (99.4%, 160\/161) and imipenem-relebactam (98.4%, 62\/63). Cefiderocol resistance was 32.4% overall and higher among NDM- (58.4%) and multi-carbapenemase producers (50.3%). Ceftazidime-avibactam plus aztreonam synergy was performed for 17.2% (286\/1658) of aztreonam-resistant metallo-beta-lactamase-producers; synergy was observed in 78.7% (225\/286) of cases. Colistin resistance was 10.6% (153\/1445) among non-intrinsically resistant species. Conclusions Whilst most UK CRE are tested for carbapenemases, coverage gaps persist. The community burden of CRE is increasing. Cefiderocol resistance is concerningly high, particularly among metallo-beta-lactamase-producers.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>DOI:&nbsp;<\/strong>10.1016\/j.ijantimicag.2026.107898<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0924857926001858\">Link to full-text<\/a> [open access - no password required]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Type of publication: Journal article Author(s): Baltas I.; Drury K.; Harrison T.; Moore N.; Lester R.; Chattaway M.A.; England B.; Cattrall J.W.S.; Donaldson C.J.; Jamal Khan D.P.; Carroll A.; Ball D.; Wareham D.W.; Pahalage R.; Banavathi K.; Drazho B.; Shorrocks<span class=\"ellipsis\">&hellip;<\/span><\/p>\n<div class=\"read-more\"><a href=\"https:\/\/www.library.sath.nhs.uk\/research\/2026\/09\/17\/carbapenem-resistant-enterobacterales-across-the-uk-a-nationwide-study-of-carbapenemase-testing-and-novel-antimicrobial-activity-2026\/\">Read more <span class=\"screen-reader-text\">Carbapenem-resistant Enterobacterales across the UK: A nationwide study of carbapenemase testing and novel antimicrobial activity (2026)<\/span><span class=\"meta-nav\"> &#8250;<\/span><\/a><\/div>\n<p><!-- end of .read-more --><\/p>\n","protected":false},"author":12,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1001,200],"tags":[1106,1002],"class_list":["post-10088","post","type-post","status-publish","format-standard","hentry","category-open-access","category-staff-publication","tag-1106","tag-gold-open-access"],"_links":{"self":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/10088","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/comments?post=10088"}],"version-history":[{"count":1,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/10088\/revisions"}],"predecessor-version":[{"id":10089,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/10088\/revisions\/10089"}],"wp:attachment":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/media?parent=10088"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/categories?post=10088"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/tags?post=10088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}